BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and ans ...

-- Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single administration of PCRX-201 -- BRISBANE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced updated three-year results and a new subset analyses demonstrating sustained efficacy and safety across all patient subgroups, including ...

BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients today reported it has received a Paragraph IV Certification Notice Letter (PIV Notice) from Qilu Pharmaceutical (Hainan) Co., Ltd., a private Chinese company. Qilu has filed an Abbreviated New Drug Application, or ANDA, with the FDA for a product claiming to be a generic equivalent of EXPAREL. In ...

-- Findings Presented at AMCP Nexus 2025 Annual Meeting -- BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced real-world evidence evaluating the clinical effectiveness and economic benefits of EXPAREL® (bupivacaine liposome injectable suspension) will be presented at the AMCP Nexus 2025 Annual Meeting taking place October 27–30 in National ...

BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients today reported it has received a Paragraph IV Certification Notice Letter (PIV Notice) from The WhiteOak Group, a subsidiary of a small private Chinese company. WhiteOak has filed an Abbreviated New Drug Application, or ANDA, with the FDA for a product claiming to be a generic of EXPAREL. Neither ...

-- Poster to be presented at American College of Rheumatology Convergence 2025 – BRISBANE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that new data from its Phase 1 clinical trial evaluating PCRX-201 (enekinragene inzadenovec), a novel gene therapy candidate for osteoarthritis of the knee, will be presented at the American College ...

SASKATOON, Saskatchewan, Oct. 17, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV:PCRX) is pleased to announce that it has filed its Final Short Form Base Shelf Prospectus dated October 14, 2025 (the “Prospectus”) with the securities commissions in each of the provinces of Canada, other than Quebec. The Prospectus allows the Corporation to ‎qualify the distribution by way of prospectus in Canada of up to $100 million of common shares, preferred ‎shares, warrants, debt s ...

Core Viewpoint - PharmaCorp RX Inc. has restated and refiled its financial statements for the interim period ended June 30, 2025, following a review by its Auditor, with certain accounting adjustments made that do not affect the overall financial position of the Corporation [1]. Financial Adjustments - The Amended Q2 2025 Statements show significant changes, including an increase in intangible assets from $4,847,651 to $6,937,651 and the addition of an acquired charter valued at $2,090,000 [2]. - The purchases of property and equipment were adjusted from $2,145,438 to $55,438, indicating a significant revision in asset reporting [2]. - The total assets and net cash used in investing activities remained unchanged despite these adjustments, indicating minimal impact on the overall financial health [3]. Notes and Revisions - Changes were made to the notes of the Amended Q2 2025 Statements, including a working capital adjustment for the acquisition of Atlantic Canada 1 amounting to $1,019,014 and the addition of the acquired charter as a line item [5]. - A footnote was added to clarify ownership restrictions under Ontario's Drug and Pharmacies Regulation Act, and amortization amounts were revised accordingly [5]. - Subsequent event notes were added to reflect the closing of the purchase of two pharmacies in Western Canada and one in Eastern Canada, as announced on October 2, 2025 [5]. Company Operations - PharmaCorp operates seven PharmaChoice Canada bannered pharmacies and plans to continue acquiring more pharmacies under this brand, as part of its strategic alliance with PharmaChoice Canada [4]. - The Corporation is also open to acquiring independently owned pharmacies and transitioning them to the PharmaChoice Canada banner [4]. - PharmaCorp actively seeks discussions with pharmacy owners regarding succession or sale, emphasizing a commitment to seamless transitions that protect legacies and serve communities [6].

Core Insights - PharmaCorp RX Inc. has completed the acquisition of three community pharmacy businesses, enhancing its presence in both Western and Eastern Canada [1][4] Western Canada Acquisitions - The company acquired two PharmaChoice Canada bannered pharmacies in Western Canada for an aggregate purchase price of $3,400,000, with 75% paid in cash and 25% through the issuance of common shares [2] - The common shares were priced based on the volume weighted average trading price on the TSX Venture Exchange over a specified period prior to the closing date [2] Eastern Canada Acquisition - PharmaCorp also acquired a PharmaChoice Canada bannered pharmacy in Eastern Canada for $5,300,000, funded through cash on hand and available credit [3] - No finder's fees were incurred in connection with these acquisitions [3] Strategic Growth - The acquisitions are part of PharmaCorp's disciplined growth strategy and strengthen its strategic alliance with PharmaChoice Canada [4] - The company aims to expand its national footprint while preserving independent legacies and ensuring continuity of care for patients [4] - PharmaCorp plans to remain active in pursuing further acquisitions in the near future [4] Company Overview - PharmaCorp currently operates seven PharmaChoice Canada bannered pharmacies and intends to continue acquiring both PharmaChoice and independently owned pharmacies [5] - The company is open to discussions with pharmacy owners considering succession or sale, emphasizing a commitment to seamless transitions [6]

SASKATOON, Saskatchewan, Sept. 29, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV:PCRX) is pleased to announce that it has filed a preliminary short form base shelf prospectus with the securities commissions in each of the provinces of Canada, other than Quebec. The base shelf prospectus, when made final and effective, will allow the Corporation to ‎qualify the distribution by way of prospectus in Canada of up to $100 million of common shares, preferred ‎shares, warran ...